Xenon Pharmaceuticals Inc (XENE)
40.56
-1.88
(-4.43%)
USD |
NASDAQ |
May 10, 16:00
40.56
0.00 (0.00%)
After-Hours: 20:00
Xenon Pharmaceuticals Cash from Investing (Quarterly): -239.73M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -239.73M |
| September 30, 2023 | 48.03M |
| June 30, 2023 | 27.90M |
| March 31, 2023 | 46.62M |
| December 31, 2022 | -14.34M |
| September 30, 2022 | -234.10M |
| June 30, 2022 | 1.317M |
| March 31, 2022 | -48.89M |
| December 31, 2021 | -215.43M |
| September 30, 2021 | 15.58M |
| June 30, 2021 | 8.192M |
| March 31, 2021 | -55.10M |
| December 31, 2020 | 43.20M |
| September 30, 2020 | -18.03M |
| June 30, 2020 | 10.93M |
| March 31, 2020 | -52.92M |
| December 31, 2019 | -60.32M |
| September 30, 2019 | 7.74M |
| June 30, 2019 | -6.628M |
| March 31, 2019 | -7.003M |
| Date | Value |
|---|---|
| December 31, 2018 | -12.56M |
| September 30, 2018 | -23.35M |
| June 30, 2018 | 1.94M |
| March 31, 2018 | 4.977M |
| December 31, 2017 | 5.803M |
| September 30, 2017 | -0.089M |
| June 30, 2017 | 9.333M |
| March 31, 2017 | 9.247M |
| December 31, 2016 | -32.23M |
| September 30, 2016 | -0.111M |
| June 30, 2016 | -15.42M |
| March 31, 2016 | -0.083M |
| December 31, 2015 | -0.143M |
| September 30, 2015 | 8.709M |
| June 30, 2015 | 0.137M |
| March 31, 2015 | 1.491M |
| December 31, 2014 | 1.04M |
| September 30, 2014 | -5.409M |
| June 30, 2014 | 1.463M |
| March 31, 2014 | -0.338M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-239.73M
Minimum
Dec 2023
48.03M
Maximum
Sep 2023
-38.74M
Average
-6.628M
Median
Jun 2019
Cash from Investing (Quarterly) Benchmarks
| Acasti Pharma Inc | -6.554M |
| Aurinia Pharmaceuticals Inc | -6.257M |
| Edesa Biotech Inc | 0.00 |
| Lexaria Bioscience Corp | -0.057M |
| ESSA Pharma Inc | 8.232M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -35.46M |
| Cash from Financing (Quarterly) | 324.01M |
| Free Cash Flow | -150.94M |
| Free Cash Flow Per Share (Quarterly) | -0.508 |
| Free Cash Flow Yield | -5.56% |